Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject

Inclusion Criteria: * Participant must be informed of the nature of the study and voluntarily agree to participate by signing an informed consent form prior to any study-specific procedures. * Participant must be a healthy male, aged 18 to 70 years (inclusive) at the time of dosing. * Participant must be judged by the Investigator or designee to be in good general health, as documented by medical history, physical examination, clinical laboratory tests, vital signs, and 12-lead electrocardiogram (ECG). Any deviations from normal ranges must be assessed and deemed not clinically significant by the Investigator or designee. * Participant must have a creatinine clearance (CrCl) value greater than 80 mL/min, as calculated by the Cockcroft-Gault equation. * Participant must agree to practice an acceptable method of contraception throughout the clinical trial, as outlined in the protocol. Exclusion Criteria: * Unwilling or unable to comply with study procedures. * Use of any investigational drug (except Hezkue/Hezkue Turbo) within 30 days prior to dosing. * History of significant renal, hepatic, cardiovascular (including orthostatic hypotension), psychiatric, neoplastic, infectious disease, or diabetes mellitus. * Clinically significant abnormal lab results, vital signs, or ECGs. * Any hepatic impairment or abnormal liver function tests. * Positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody. * Clinically significant illness within 28 days prior to dosing. * Known hypersensitivity to sildenafil, tadalafil, vardenafil, or any component of the investigational product (e.g., peppermint oil). * History of significant food or drug allergies. * History of drug abuse within the past year or positive drug screen at screening. * Regular alcohol consumption exceeding 15 units per week. * Use of CYP450 enzyme inhibitors within 14 days prior to dosing. * Use of CYP450 enzyme inducers or St. John's Wort within 28 days prior to dosing. * Blood donation or significant blood loss within 3 months before screening. * Plasma donation within 14 days prior to first dose. * Inadequate venous access for repeated blood sampling. * Difficulty fasting or inability to consume standardized meals. * Intolerance to fatty foods or inability to consume a high-fat, high-calorie breakfast. * Difficulty swallowing. * Regular use of tobacco or nicotine products within 4 weeks prior to screening. * Major surgery within 3 months or minor surgery within 1 month before screening. * Considered unsuitable for study participation by the Investigator. * Institutionalized status. * Use of hormone replacement therapy within 6 months prior to dosing. * Consumption of Seville oranges, grapefruit, or pomelo within 7 days prior to dosing. * Consumption of caffeine, xanthine-containing products, or poppy seeds within 48 hours prior to dosing. * Receipt of a COVID-19 vaccine within 3 days prior to dosing. * Presence of braces, retainers, dentures, partial dentures, or tongue piercings. * Use of nitric oxide donors, organic nitrates/nitrites, antihypertensive medications, or PDE5 inhibitors within 14 days of dosing. * Blood pressure or heart rate outside acceptable ranges: * Systolic BP \<90 or \>140 mmHg * Diastolic BP \<50 or \>90 mmHg * Heart rate \<50 or \>100 bpm